ABBOTT LABORATORIES acquires Solvay Pharmaceuticals
Snapshot
ABBOTT LABORATORIES acquired Solvay Pharmaceuticals for EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments in February 2010. The transaction was structured as all cash. Solvay Pharmaceuticals is a Brussels, Belgium (global, emerging-markets weighted)-based Pharmaceuticals business.
- Acquirer
- ABBOTT LABORATORIES
- Target
- Solvay Pharmaceuticals
- Value
- EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments
- Date
- February 2010
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
ABBOTT LABORATORIES acquired Solvay Pharmaceuticals for EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments, a transaction completed in February 2010, structured as all cash.
Solvay Pharmaceuticals operates in Pharmaceuticals, is based in Brussels, Belgium (global, emerging-markets weighted). Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint.
Diversifies Abbott's pharmaceutical products and expands its international growth platform, supporting long-term strategic growth in emerging markets.
Diversified pharmaceutical portfolio with a strong emerging-markets growth platform. Integrated into Abbott's pharmaceutical products business
No advisory firms have been disclosed for this transaction.